AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 126 min read$ISRG

Two Years Of Growth Barely Change What You Pay For Intuitive Surgical

Intuitive Surgical (ISRG) is trading around $401.23, about 32% below its 52-week high and down 15% over 12 months versus a 22% S&P 500 gain. The stock trades at ~37.7x trailing adjusted earnings; analysts expect ~$12.08/share by 2027, implying ~33x. Forecast growth assumes margin give-back, while da Vinci placements rose 18% YoY in Q2 2026 and instrument pricing for 2027 is not finalized.

Original reporting
finance.yahoo.com
Published Aug 12, 2026, 5:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 7:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Two Years Of Growth Barely Change What You Pay For Intuitive Surgical — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ISRGNeutralMed
01

Why it matters

If ISRG quantifies favorable instrument pricing economics on its next earnings call, forward earnings could be revised up, compressing the discount implied by the current multiple. If quantified effects are less favorable, the market’s margin give-back concern could intensify and keep the multiple capped.

02

Market read

The trading focus is the gap between consensus 2027 earnings and ISRG’s not-yet-quantified instrument pricing impact, which can swing forward estimates at the next earnings call.

03

What to watch

The piece does not quantify how much the extended use program changes instrument economics versus procedure volumes, so traders may be underestimating the net effect on gross profit dollars rather than margins alone.

Relevance 5/10Novelty 4/10Timing: ahead of ISRG’s next earnings call where it will quantify 2027 instrument pricing effects

Background

The article frames ISRG’s current valuation versus trailing and forward earnings, then focuses on why the 2027 multiple is uncertain due to instrument pricing not yet set.

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Article argues ISRG’s 2027 valuation depends on instrument pricing it has not finalized, despite rising da Vinci placements and 2026 gross margin guidance.

Expected impact

Near-term trading likely hinges on whether the next earnings call quantifies the 2027 instrument pricing impact; until then, the market may keep a discount or volatility around forward estimates.

Evidence & confidence

The newest concrete fact is that ISRG has not finalized 2027 instrument pricing and will quantify effects on its next earnings call, directly affecting forward earnings assumptions and the multiple.

Market effects

Sector

Highlights valuation risk for surgical robotics names when forward instrument economics are not yet specified, reinforcing sensitivity to margin and pricing assumptions.

Regional

None stated.

Global

None stated.

Counterpoint

What could challenge this read

The article’s uncertainty on 2027 instrument pricing may be overstated if adoption and upgrades (da Vinci 5) continue to lift recurring revenue faster than expected, offsetting any margin give-back.

Key entities

  • company
    Intuitive Surgical

    Surgical robotics company discussed for valuation, da Vinci placements, gross margin guidance, and unresolved 2027 instrument pricing.

  • product
    da Vinci system

    Robotics platform whose placements and upgrades are cited as driving adoption and recurring revenue.

  • program
    Extended use program

    Program starting in 1H 2027 that increases instrument uses and lowers customer cost per procedure, with pricing impact not yet finalized.

Read at source← All news

Related articles

AUG 31
$ISRGMedAI 8/10

New da Vinci Surgical Robot Secures Marketing Approval: Entering Olympus’ Core Dominant Surgical Market

Intuitive Surgical received FDA approval for its flexible gastrointestinal robot, IG1000, marking its entry into a market dominated by Olympus. The company plans to refine the product before commercial launch, focusing on clinical benefits and user experience. Analysts note the product's force feedback and suturing capabilities, highlighting Intuitive's strategic expansion beyond its da Vinci surgical robots.

eu.36kr.com3 min
AUG 25
$NKELow

Can These Beaten Down Stocks Bounce Back?

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

yahoo.com2 min
AUG 24
$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

yahoo.com3 min
AUG 23
$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.

yahoo.com3 min